Figure 4.
C-MET degradation effects of D10 and D15 were mediated through the ubiquitin proteasome pathway and the formation of ternary complex. (A–B) EBC-1 (A) and Hs746T (B) cells were pretreated with MLN-4924 (10 μmol/L), MG132 (10 μmol/L) for 6 h, followed by treatment with D10 and D15 at 10 nmol/L for 72 h. (C–D) EBC-1 (C) and Hs746T (D) cells were pretreated tepotinib (100 nmol/L) or thalidomide (10 μmol/L) for 6 h, followed by treatment with D10 and D15 at 10 nmol/L for 72 h.